Literature DB >> 24531844

Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla.

N Verloh1, M Haimerl, F Zeman, M Schlabeck, A Barreiros, M Loss, A G Schreyer, C Stroszczynski, C Fellner, P Wiggermann.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the usefulness of Gd-EOB-DTPA-enhanced 3-T MRI to determine the hepatic functional reserve expressed by the model for end-stage liver disease (MELD) score.
METHODS: A total of 121 patients with normal liver function (NLF; MELD score ≤ 10) and 29 patients with impaired liver function (ILF; MELD score > 10) underwent contrast-enhanced MRI with a hepatocyte-specific contrast agent at 3T. T1-weighted volume interpolated breath-hold examination (VIBE) sequences with fat suppression were acquired before and 20 min after contrast injection. Relative enhancement (RE) between plain signal intensity and contrast-enhanced signal intensity was calculated and was used to determine Gd-EOB-DTPA uptake into the liver parenchyma for patients with different MELD scores.
RESULTS: RE differed significantly (p ≤ 0.001) between patients with NLF (87.2 ± 29.5 %) and patients with ILF (45.4 ± 26.5 %). The optimal cut-off value for RE to differentiate NLF from ILF was 47.7 % (AUC 0.87). This cut-off value showed a sensitivity of 82.8 % and a specificity of 92.7 % for the differentiation of the analysed groups.
CONCLUSION: Gd-EOB-DTPA uptake in hepatocytes is strongly affected by liver function. Gd-EOB-DTPA-enhanced MRI and assessment of RE during the hepatobiliary phase (HBP) may serve as a useful image-based test in liver imaging for determining regional and global liver function. KEY POINTS: Hepatic uptake of Gd-EOB-DTPA is strongly affected by liver function. Relative enhancement during HBP in GD-EOB-DTPA MRI correlates with the MELD score. Assessment of relative enhancement may help improve treatment in routine clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24531844     DOI: 10.1007/s00330-014-3108-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  40 in total

1.  Mechanism of hepatic uptake of gadoxetate disodium.

Authors:  H J Weinmann; H Bauer; T Frenzel; A Mühler; W Ebert
Journal:  Acad Radiol       Date:  1996-08       Impact factor: 3.173

2.  Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.

Authors:  O Dahlqvist Leinhard; N Dahlström; J Kihlberg; P Sandström; T B Brismar; O Smedby; P Lundberg
Journal:  Eur Radiol       Date:  2011-10-09       Impact factor: 5.315

3.  Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients.

Authors:  Bang-Bin Chen; Chao-Yu Hsu; Chih-Wei Yu; Shwu-Yuan Wei; Jia-Horng Kao; Hsuan-Shu Lee; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2011-08-31       Impact factor: 5.315

4.  Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors.

Authors:  Victoria Chernyak; Jane Kim; Alla M Rozenblit; Fernanda Mazzoriol; Zina Ricci
Journal:  J Magn Reson Imaging       Date:  2011-05-23       Impact factor: 4.813

Review 5.  Liver functional reserve estimation: state of the art and relevance to local treatments.

Authors:  Fotini Manizate; Spiros P Hiotis; Daniel Labow; Sasan Roayaie; Myron Schwartz
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

6.  Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.

Authors:  Tsutomu Tamada; Katsuyoshi Ito; Atsushi Higaki; Koji Yoshida; Akihiko Kanki; Tomohiro Sato; Hiroki Higashi; Teruki Sone
Journal:  Eur J Radiol       Date:  2011-02-18       Impact factor: 3.528

Review 7.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

8.  Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.

Authors:  Taku Tajima; Hidemasa Takao; Hiroyuki Akai; Shigeru Kiryu; Hiroshi Imamura; Yasushi Watanabe; Jyunichi Shibahara; Norihiro Kokudo; Masaaki Akahane; Kuni Ohtomo
Journal:  J Comput Assist Tomogr       Date:  2010 May-Jun       Impact factor: 1.826

9.  Quantitative evaluation of liver function with MRI Using Gd-EOB-DTPA.

Authors:  Hun-Kyu Ryeom; Seong-Hun Kim; Jong-Yeol Kim; Hye-Jeong Kim; Jong-Min Lee; Yong-Min Chang; Yong-Sun Kim; Duk-Sik Kang
Journal:  Korean J Radiol       Date:  2004 Oct-Dec       Impact factor: 3.500

10.  Molecular mechanisms for the hepatic uptake of magnetic resonance imaging contrast agents.

Authors:  L Pascolo; F Cupelli; P L Anelli; V Lorusso; M Visigalli; F Uggeri; C Tiribelli
Journal:  Biochem Biophys Res Commun       Date:  1999-04-21       Impact factor: 3.575

View more
  50 in total

1.  3.0 Tesla magnetic resonance imaging: A new standard in liver imaging?

Authors:  Rossano Girometti
Journal:  World J Hepatol       Date:  2015-07-28

2.  Can functional parameters from hepatobiliary phase of gadoxetate MRI predict clinical outcomes in patients with cirrhosis?

Authors:  Kumar Sandrasegaran; Enming Cui; Reem Elkady; Pauley Gasparis; Gitasree Borthakur; Mark Tann; Suthat Liangpunsakul
Journal:  Eur Radiol       Date:  2018-04-12       Impact factor: 5.315

3.  Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yuichiro Kubo; Yoshiki Asayama; Yasuhiro Ushijima; Yukihisa Takayama; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Hiroshi Honda
Journal:  Eur Radiol       Date:  2014-07-26       Impact factor: 5.315

Review 4.  Molecular changes in hepatic metabolism and transport in cirrhosis and their functional importance.

Authors:  Christoph G Dietrich; Oliver Götze; Andreas Geier
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

5.  The inhomogeneous distribution of liver function: possible impact on the prediction of post-operative remnant liver function.

Authors:  Henrik Nilsson; Silja Karlgren; Lennart Blomqvist; Eduard Jonas
Journal:  HPB (Oxford)       Date:  2014-10-09       Impact factor: 3.647

6.  A New Model for MR Evaluation of Liver Function with Gadoxetic Acid, Including Both Uptake and Excretion.

Authors:  Daniel Truhn; Christiane K Kuhl; Alexander Ciritsis; Alexandra Barabasch; Nils A Kraemer
Journal:  Eur Radiol       Date:  2018-06-15       Impact factor: 5.315

7.  Evaluation of Magnetic Resonance (MR) Biomarkers for Assessment of Response With Response Evaluation Criteria in Solid Tumors: Comparison of the Measurements of Neuroendocrine Tumor Liver Metastases (NETLM) With Various MR Sequences and at Multiple Phases of Contrast Administration.

Authors:  Gustavo Felipe Luersen; W Wei; Eric P Tamm; Priya R Bhosale; Janio Szklaruk
Journal:  J Comput Assist Tomogr       Date:  2016 Sep-Oct       Impact factor: 1.826

Review 8.  Liver surgery in cirrhosis and portal hypertension.

Authors:  Christina Hackl; Hans J Schlitt; Philipp Renner; Sven A Lang
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

9.  Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests.

Authors:  Guido M Kukuk; Stephanie G Schaefer; Rolf Fimmers; Dariusch R Hadizadeh; Samer Ezziddin; Ulrich Spengler; Hans H Schild; Winfried A Willinek
Journal:  Eur Radiol       Date:  2014-07-17       Impact factor: 5.315

10.  Porto-sinusoidal vascular disease with portal hypertension versus liver cirrhosis: differences in imaging features on CT and hepatobiliary contrast-enhanced MRI.

Authors:  Ji Hun Kang; Do Hyung Kim; So Yeon Kim; Hyo Jeong Kang; Jung Bok Lee; Kyoung Won Kim; Seung Soo Lee; Jonggi Choi; Young-Suk Lim
Journal:  Abdom Radiol (NY)       Date:  2020-10-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.